{"transactions":[{"id":713054,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31506,"kind":"person","name":"Friend John E. II","position":1,"cik":"0001704021","reported_name":"Friend John E. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Share Units","published_at":"2026-07-08T20:59:05.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a board-approved award of 150,000 restricted share units (\"RSUs\"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a board-approved award of 150,000 restricted share units (\"RSUs\"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents a board-approved award of 150,000 restricted share units (\"RSUs\"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer."}],"balance_after":150000,"derivative":{"underlying":"ADSs","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-26-076430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076430/ownership.xml","form_type":"4"}},{"id":713053,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31506,"kind":"person","name":"Friend John E. II","position":1,"cik":"0001704021","reported_name":"Friend John E. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:59:05.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":500000,"derivative":{"exercise_price":6.78,"underlying":"ADSs","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-26-076430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076430/ownership.xml","form_type":"4"}},{"id":2806380,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31506,"kind":"person","name":"Friend John E. II","position":1,"cik":"0001704021","reported_name":"Friend John E. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-03-05T22:46:09.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date."}],"balance_after":330000,"derivative":{"exercise_price":1.74,"expiration_date":"2021-03-04","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001104659-21-032851","document":"tm218888d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704021/000110465921032851/tm218888d1_4.xml","form_type":"4"}},{"id":3088975,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31506,"kind":"person","name":"Friend John E. II","position":1,"cik":"0001704021","reported_name":"Friend John E. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-07-06T10:06:29.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in three equal installments beginning on the first anniversary of the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":1.34,"expiration_date":"2030-07-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-20-080841","document":"tm2023996d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704021/000110465920080841/tm2023996d2_4.xml","form_type":"4"}},{"id":3790687,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31506,"kind":"person","name":"Friend John E. II","position":1,"cik":"0001704021","reported_name":"Friend John E. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-10-15T23:48:21.000Z","date":"2018-10-12","kind":"grant","acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant was divided into a definitive grant of 29,820 shares, which vest as to all shares on the first anniversary of the grant date, and a contingent grant of 33,180 shares, which are subject to the following conditions: (i) approval by Cellectar?s stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation?s 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest over a period of three years from the grant date, vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date."}],"balance_after":63000,"derivative":{"exercise_price":2.61,"expiration_date":"2028-10-12","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001144204-18-053876","document":"tv504840_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704021/000114420418053876/tv504840_form4.xml","form_type":"4"}},{"id":4350738,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31506,"kind":"person","name":"Friend John E. II","position":1,"cik":"0001704021","reported_name":"Friend John E. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Medical Officer"}}],"security":"Common stock","published_at":"2017-04-18T22:30:11.000Z","date":"2017-04-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Common stock grant that vests in equal annual increments over a period of three years from the date of grant."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001144204-17-020952","document":"v464509_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704021/000114420417020952/v464509_form4.xml","form_type":"4"}}]}